Healthcare divestitures
Completed divestitures by sellers in this sector, from SEC 8-K filings, newest first. The sector is the seller's SEC industry code.
6 completed divestitures.
| Filed | Seller | Business sold | Buyer | Disclosed value | Seller sector | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | International Stem Cell CORP (ISCO) | 100% of the membership interests of its wholly-owned subsidiary Lifeline Cell Technology, LLCWhat the filing says"Exhibit 99.1 INTERNATIONAL STEM CELL CORPORATION Unaudited Pro Forma Financial Statements On September 1, 2026, International Stem Cell Corporation (the Company ) completed the sale of 100% of the membership interests of its wholly-owned subsidiary Lifeline Cell Technology, LLC ( LCT ), to American Type Culture Collection, Inc. ( ATCC ) pursuant to the Membership Interest Purchase Agreement (the MIPA ) dated July 10, 2026, for an adjusted purchase price of $25,250,000 (base purchase price of $25,000,000 plus a fixe" | American Type Culture Collection, Inc. | $25.3M | Healthcare | SEC 8-K exhibit |
| 2026-08-21 | ELUTIA INC. (ELUT) | SimpliDerm human acellular dermal matrix businessWhat the filing says"(Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million" | Cellution Biologics Inc. | $11M | Healthcare | SEC 8-K exhibit |
| 2026-08-13 | MACROGENICS INC (MGNX) | GMP drug substance manufacturing operationsWhat the filing says"In July, MacroGenics announced the completion of the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC (collectively, Bora) for a previously disclosed base purchase price of $122.5 million" | Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC | $123M | Healthcare | SEC 8-K exhibit |
| 2026-08-03 | TELEFLEX INC (TFX) | Original Equipment Manufacturing and Development Services businessWhat the filing says"On August 3, 2026 (the " Closing Date "), Teleflex Incorporated (the " Company ") completed the previously announced sale of its Original Equipment Manufacturing and Development Services business (the " OEM Business ") to Lotus US Bidco Inc., a Delaware corporation (the " OEM Purchaser "), pursuant to the Equity Purchase Agreement, dated December 9, 2025 (the " OEM Agreement "), by and between the Company and the OEM Purchaser (the " OEM Transaction ")" | Lotus US Bidco Inc. | $1.5bn | Healthcare | SEC 8-K |
| 2026-07-07 | CareDx, Inc. (CDNA) | Lab Products businessWhat the filing says"Nasdaq CDNA) - The Transplant Company , a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific" | Eurobio Scientific | Not disclosed | Healthcare | SEC 8-K exhibit |
| 2026-05-07 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | CDMO and Cell Solutions businessesWhat the filing says"Divestiture Update On May 6, 2026, the Company completed the previously announced divestiture of the CDMO and Cell Solutions businesses to GI Partners" | GI Partners | $200M | Healthcare | SEC 8-K exhibit |
What counts, and where it comes from.
A row is a completed sale or spin-off of a business unit (a business, segment, division or named subsidiary) that the seller reported in a Form 8-K filed with the SEC during the month (or, on a weekly page, the ISO week, Monday to Sunday): under Item 2.01, completion of acquisition or disposition of assets, or in a press release attached to the filing that says the sale has closed.
Sales of buildings, loan books or securities are left out, as is the sale of a whole company. Every field is taken from the filing's own words, and each row keeps the sentence it came from. Where a filing does not name the buyer or the price, the table says so rather than filling the gap. The sector is the seller's SEC industry code, not the unit's.
Source: SEC EDGAR full-text search and the filings themselves. Public filings only. None of these transactions is an FIH.com mandate, and nothing here is advice.
Planning a carve-out of your own?
The filings show what closed. The work that decides the price happens months earlier: the perimeter, the standalone numbers and the transition services.
Every mandate startswith one conversation.
Tell us what you are considering. A senior advisor from FIH will come back with a straight read on value, timing and who would actually buy it, before you commit to anything.
- Confidential. Nothing you share leaves the advisory team.
- Success-based. No retainer, no upfront fees, no obligation.
- A senior FIH advisor responds within one business day.